Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $653.50M
• Dividend Yield: N/A
• Average Volume (3M): 102.52K
• Price to Earnings (P/E): 188.7
• Beta (1Y): 1.80
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 90,890,380
• 10 Day Avg. Volume: 112,833
• 30 Day Avg. Volume: 102,519
• PEG Ratio: -0.78
• Price to Book (P/B): 16.26
• Price to Sales (P/S): 9.74
• P/FCF Ratio: -172.88
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 6.89
• Enterprise Value/Gross Profit: 7.22
• Enterprise Value/Ebitda: 49.18
• 1Y Price Target: $18.00
• Price Target Upside: 150.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $8.50 ▲(18.22% Upside)

Gyre Therapeutics' overall stock score is driven by strong corporate events and positive technical indicators. However, the high P/E ratio suggests overvaluation, and cash flow management issues pose risks. The company's robust balance sheet and profitability provide a solid foundation, but improvements in cash flow are necessary for sustained financial health.

Positive Factors

Strong Profitability

High gross and net profit margins indicate efficient cost management and enhanced profitability, supporting long-term financial health.

Positive Phase 3 Results

Successful Phase 3 results enhance Gyre's competitive edge and pave the way for future product launches, strengthening market position.

Robust Balance Sheet

Low leverage and high return on equity reflect financial stability and effective use of equity, ensuring long-term sustainability.

Negative Factors

Cash Flow Management Issues

Declining free cash flow growth indicates potential cash flow issues, which could strain operations and limit financial flexibility.

Low Cash Flow Coverage Ratios

Low cash flow coverage ratios suggest insufficient cash generation to cover net income, highlighting a need for improved cash management.

Modest Revenue Growth

Modest revenue growth may limit Gyre's ability to scale operations and capture market share, impacting long-term growth potential.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

How the Company Makes Money

Gyre Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may secure funding through partnerships with larger pharmaceutical firms, which can include milestone payments as products progress through clinical trials. Additionally, GYRE may receive royalties from product sales once therapies are successfully commercialized. Grant funding from government and non-profit organizations aimed at supporting innovative healthcare solutions also contributes to the company's revenue streams. Collaborations with academic institutions for research initiatives further enhance GYRE's financial stability.

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics shows strong profitability with a high gross profit margin and improved net profit margin. The balance sheet is robust with low leverage and high return on equity. However, cash flow management is a concern with significant declines in free cash flow growth and low cash flow coverage ratios.

Income Statement

Gyre Therapeutics shows a strong gross profit margin of 95.58% TTM, indicating efficient cost management. The net profit margin improved significantly to 28.79% TTM, reflecting enhanced profitability. Revenue growth is modest at 4.97% TTM, but the company has shown resilience with a positive trajectory from previous periods of decline. However, EBIT and EBITDA margins are relatively low, suggesting room for operational efficiency improvements.

Balance Sheet

The company's balance sheet is strong with a low debt-to-equity ratio of 0.015 TTM, indicating minimal leverage and financial stability. Return on equity is impressive at 62.70% TTM, showcasing effective use of equity to generate profits. The equity ratio is healthy, reflecting a solid capital structure. However, past periods showed negative equity, which could pose a risk if not managed carefully.

Cash Flow

Cash flow analysis reveals challenges, with a significant decline in free cash flow growth at -3765.82% TTM. The operating cash flow to net income ratio is low at 0.05 TTM, indicating potential cash flow issues. The negative free cash flow to net income ratio suggests the company is not generating sufficient cash from operations to cover its net income, highlighting a need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	107.27M	105.76M	113.45M	102.29M	7.34M	20.95M
Gross Profit	102.42M	101.87M	108.81M	97.50M	-332.00K	11.79M
EBITDA	15.03M	17.82M	20.33M	10.33M	-87.64M	-56.10M
Net Income	6.65M	12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet
Total Assets	159.38M	125.41M	116.54M	84.75M	55.66M	94.85M
Cash, Cash Equivalents and Short-Term Investments	40.40M	26.67M	33.51M	25.18M	46.85M	79.35M
Total Debt	1.17M	1.60M	409.00K	613.00K	2.38M	1.64M
Total Liabilities	21.97M	27.00M	102.59M	12.54M	14.57M	18.78M
Stockholders Equity	101.92M	63.32M	-15.83M	42.52M	41.09M	76.07M
Cash Flow
Free Cash Flow	1.35M	-6.77M	17.31M	5.68M	-84.59M	-55.31M
Operating Cash Flow	3.88M	-3.64M	25.89M	10.68M	-83.75M	-55.05M
Investing Cash Flow	-4.33M	-19.88M	-19.76M	-13.81M	48.19M	9.66M
Financing Cash Flow	25.02M	2.10M	2.50M	0.00	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 7.19 is below the 20-day moving average (MA) of 7.66, below the 50-day MA of 7.79, and below the 200-day MA of 8.16, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 39.62 is Neutral, neither overbought nor oversold. The STOCH value of 19.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GYRE	64 Neutral	$653.50M	188.71	8.06%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	50 Neutral	$985.68M	-6.46	-30.16%	―	31.11%	-46.75%
KALV	45 Neutral	$798.13M	-3.95	―	―	―	-13.14%
TERN	45 Neutral	$4.51B	-41.07	-29.12%	―	―	12.45%
TYRA	41 Neutral	$1.39B	-13.85	-34.75%	―	―	-17.01%
MBX	38 Underperform	$1.44B	-13.41	-24.43%	―	―	-44.79%

Gyre Therapeutics Corporate Events

Gyre Therapeutics Announces Positive Phase 3 Results

On September 10, 2025, Gyre Therapeutics released an updated corporate presentation highlighting its strategic initiatives and clinical advancements. The company announced positive Phase 3 results for Hydronidone in treating CHB-associated liver fibrosis, with significant improvements in fibrosis regression and inflammation. These developments underscore Gyre’s commitment to expanding its therapeutic pipeline and strengthening its market position in fibrosis treatments, potentially impacting stakeholders by enhancing its competitive edge and paving the way for future product launches.